Drug Trial Radar · NCT05671029
Thorough QT/QTc of Pritelivir in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Dec 4, 2022
Primary completion
May 18, 2023
Study completion May 18, 2023
Sponsor
- Lead sponsor
- AiCuris Anti-infective Cures AGIndustry
- Sponsor type
- Industry
- First posted
- Jan 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 clinical trial was a double-blind, single-center, randomized and placebo-controlled trial in which healthy male and female subjects received in 2 parallel-groups daily oral doses of pritelivir (Group 1) or matching placebo (Group 2). Within Group 2, a single oral administration of moxifloxacin (positive control) and corresponding matching placebo was administered in a 2-sequence crossover design (nested crossover).
Conditions
- Healthy Subjects
Interventions
Pritelivir and moxifloxacin placeboDrug
oral administration
Pritelivir placebo, moxifloxacin and moxifloxacin placeboDrug
oral administration
Pritelivir placebo, moxifloxacin placebo and moxifloxacinDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of Pritelivir on the QTcF Interval (QTc Using Fridericia Correction Method) in Comparison With Placebo in Male and Female Subjects.Time frame: Day -2 to Day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Richmond Pharmacology Ltd
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.